Table 2 Cohorts 7–9 – Adjuvant disease cohorts and defined standard of care ICI-containing treatment regimens
Cohort | Disease | Regimen | Primary outcome measure |
|---|---|---|---|
Cohort 7 | Resected AJCC stage 3 or 4 melanoma | Anti-PD-1 monotherapy (nivolumab or pembrolizumab) | 1 year & 2 year RFS |
Cohort 8 | Resected renal cancer | Durvalumab | 1 year & 2 year RFS |
Cohort 9 | Resected renal cancer | Durvalumab+tremelimumab | 1 year & 2 year RFS |